Muireann Bolger

Key details

Muireann Bolger is deputy editor of World Intellectual Property Review and Life Sciences Intellectual Property Review in London, where she covers trademarks, brands, as well as wider developments across the intellectual property sector.

She regularly attends and covers major IP conferences around the world, reporting on the latest legal, commercial and policy developments and interviewing leading figures from across the sector. She has also co-authored industry reports with leading IP organisations, including the International Trademark Association (INTA).

She is the editor of the website’s Community & Inclusion channel and the annual Influential Women in IP list, which celebrates the achievements and contributions of leading women across the IP sector.

Originally from Ireland, Muireann has nearly two decades of experience reporting on brand developments, strategy, and wider business issues.

In her current role, she writes and edits news and analysis for an international audience of IP professionals, while also championing inclusion within the profession.

Reset all filters
Article Type
Channels & Sectors
Geography
Company
Refine search
Total results: 415

Articles by Muireann Bolger

SCOTUS asks for SG’s view on enablement in antibody dispute
Americas
The US Supreme Court has asked the Solicitor General to wade in on a case centring on the legal concept of enablement that is the crux of an antibody patent dispute between Amgen and Sanofi.   19 April 2022
Pharma patent filings rise at EPO amid pandemic
Europe
Patent applications in Europe reached record levels during 2021 amid the COVID-19 pandemic, according to a new report by the European Patent Office.   5 April 2022
COVID-19 IP waiver faces uncertain future
Americas
The future of the IP waiver related to the COVID-19 vaccine looks uncertain after the US Trade Representative confirmed no agreements had yet been reached between US, the EU, India and South Africa.   31 March 2022
Pharma
Gilead Sciences has failed to prevent insurer Aetna from pursuing its lawsuit in a US state court, as it faces a spate of antitrust complaints alleging that it used pay-for-delay deals to maintain the high costs of HIV drugs.   31 March 2022
Pharma
Sun Pharmaceuticals has agreed to pay $485 million to settle an antitrust lawsuit relating to a generic drug application filed by its subsidiary, Ranbaxy, ending years of litigation.   24 March 2022
Americas
Takeda Pharmaceutical and Arbor Pharmaceuticals are seeking to block Turkey-based EastPharma from releasing a generic version of the blockbuster high blood pressure medication, Edarbi.   22 March 2022
Americas
US pharma company HDT Bio has accused Emcure Pharmaceuticals of the “blatant theft” of its COVID-19 vaccine technology in a new lawsuit.   22 March 2022
Americas
Eli Lilly has failed to convince a US judge to toss a patent infringement lawsuit filed by Teva Pharmaceuticals in a dispute over a migraine medication.   17 March 2022
Americas
A subsidiary of Tokyo-based FujiFilm has announced that it has filed a patent infringement lawsuit against ultrasound machine maker Butterfly Network.   10 March 2022
Americas
The US Chamber of Commerce has warned against the proposed Covid-19 IP waiver, in its latest International IP Index, a report measuring the quality of global IP systems.   3 March 2022

Not finding what you're looking for, please try resetting your applied search and filters,
or try the
full site search.